Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Teruhiro Utsugi News

Teruhiro Utsugi News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Teruhiro Utsugi. Real-time updates on events, politics, business and more.

Taiho Oncology, Inc.: FDA Approves Taiho's LYTGOBI (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

September 30, 2022
LYTGOBI (pronounced "light-GOH-bee") delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI
United States New Jersey Kostenloser Wertpapierhandel Teruhiro Utsugi Lipika Goyal Judy Kay Moore
Source: finanznachrichten.de

Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program

January 13, 2021
Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program   TOKYO, Japan; 13 January, 2021 Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug d...
United States Harren Jhoti Teruhiro Utsugi Nick Haining Taiho Pharmaceutical Co Ltd Astex Pharmaceuticals
Source: pharmiweb.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science